Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

Mesher, David; Soldan, Kate; Lehtinen, Matti; Beddows, Simon; Brisson, Marc; Brotherton, Julia M.L.; Chow, Eric P.F.; Cummings, Teresa; Drolet, Mélanie; Fairley, Christopher K.; Garland, Suzanne M.; Kahn, Jessica A.; Kavanagh, Kimberley; Markowitz, Lauri; Pollock, Kevin G.; Söderlund-Strand, Anna; Sonnenberg, Pam; Tabrizi, Sepehr N.; Tanton, Clare; Unger, Elizabeth; Thomas, Sara L.

doi:10.3201/eid2210.160675

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

Published Date:

Oct 2016

Publisher's site:

http://dx.doi.org/10.3201/eid2210.160675 New Site Icon

Source:

Emerg Infect Dis. 22(10):1732-1740.

[PDF - 964.03 KB]

Details:

Personal Authors:

Mesher, David ; Soldan, Kate ; Lehtinen, Matti ; Beddows, Simon ; Brisson, Marc ; ... More ▼

Keywords:

[+]

Pubmed ID:

27648688

Pubmed Central ID:

PMC5038419

Description:

We analyzed human papillomavirus (HPV) prevalences during prevaccination and postvaccination periods to consider possible changes in nonvaccine HPV genotypes after introduction of vaccines that confer protection against 2 high-risk types, HPV16 and HPV18. Our meta-analysis included 9 studies with data for 13,886 girls and women ≤19 years of age and 23,340 women 20-24 years of age. We found evidence of cross-protection for HPV31 among the younger age group after vaccine introduction but little evidence for reductions of HPV33 and HPV45. For the group this same age group, we also found slight increases in 2 nonvaccine high-risk HPV types (HPV39 and HPV52) and in 2 possible high-risk types (HPV53 and HPV73). However, results between age groups and vaccines used were inconsistent, and the increases had possible alternative explanations; consequently, these data provided no clear evidence for type replacement. Continued monitoring of these HPV genotypes is important.

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Funding:

R01 AI073713/AI/NIAID NIH HHS/United States
R01 AI104709/AI/NIAID NIH HHS/United States

Supporting Files:

16-0675-F1.gif	image/gif
16-0675-F1.jpg	image/jpeg
16-0675-F2.gif	image/gif
16-0675-F2.jpg	image/jpeg
16-0675-F3.gif	image/gif
16-0675-F3.jpg	image/jpeg
16-0675-Techapp-s1.pdf	application/pdf
16-0675.nxml	application/octet-stream

No Related Documents.

You May Also Like:

Evaluating Human Papillomavirus Vaccination Programs

Personal Author:

Taira, Al V.; Neukermans, Christopher P.; Sanders, Gillian D.;

Published:

Nov 2004

Source:

Emerg Infect Dis. 10(11):1915-1923.

Description:

Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated vaccination programs with a vaccine against HPV-16 and HPV-18. We de...

File Type:

[PDF - 346.88 KB]
Human papillomavirus vaccination : recommendations of the Advisory Committee on Immunization Practices (ACIP)

Personal Author:

Markowitz, Lauri E.; Dunne, Eileen F.; Saraiya, Mona; Chesson, Harrell W.; Curtis, C. Robinette; Gee, Julianne; Bocchini, Joseph A.; Unger, Elizabeth R., 1951-;

Corporate Author:

United States. Advisory Committee on Immunization Practices.; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of STD Prevention.;

Published:

August 29, 2014

Source:

MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30.

Series:

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 63, RR-05

Description:

This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's A...

Status:

current

File Type:

[PDF - 757.82 KB]
Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012

Personal Author:

Hariri, Susan; Markowitz, Lauri E.; Bennett, Nancy M.; Niccolai, Linda M.; Schafer, Sean; Bloch, Karen; Park, Ina U.; Scahill, Mary W.; Julian, Pamela; Abdullah, Nasreen; Levine, Diane; Whitney, Erin; Unger, Elizabeth R.; Steinau, Martin; Bauer, Heidi M.; Meek, James; Hadler, James; Sosa, Lynn; Powell, Suzanne E.; Johnson, Michelle L.; Group, HPV-IMPACT Working;

Published:

Sep 2015

Source:

Emerg Infect Dis. 21(9):1557-1561.

Description:

In 2007, five Emerging Infections Program (EIP) sites were funded to determine the feasibility of establishing a population-based surveillance system for monitoring the effect of human papillomavirus (HPV) vaccine on pre-invasive cervical lesions. Th...

File Type:

[PDF - 474.11 KB]
Human Papillomavirus Vaccination Strategies

Personal Author:

Cachafeiro, Santiago Pérez

Published:

Dec 2007

Source:

Emerg Infect Dis. 13(12):1958-1959.

File Type:

[PDF - 123.14 KB]
Novel Cryptosporidium Genotypes in Sporadic Cryptosporidiosis Cases: First Report of Human Infections with a Cervine Genotype

Personal Author:

Ong, Corinne S. L.; Eisler, Diane L.; Alikhani, Alireza; Fung, Vicki W. K.; Tomblin, Joan; Bowie, William R.; Isaac-Renton, Judith L.;

Published:

Mar 2002

Source:

Emerg Infect Dis. 8(3):263-268.

Description:

In this study, we genotyped parasites from the fecal specimens of sporadic cryptosporidiosis cases in British Columbia from 1995 to 1999. Genotyping was conducted by polymerase chain amplification of the internal transcribed spacer region, a hypervar...

File Type:

[PDF - 425.88 KB]